ArticleDiscover oncology2025
Integrated summary data-based Mendelian randomization and colocalization analysis reveals TNNT3 as a target of Deer-Antler-Ginseng-formula for triple-negative breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs an aggressive tumor type with poor prognosis, high recurrence and metastasis tendency, and lack of effective therapeutic targets, triple-negative breast cancer (TNBC) not only poses a remarkable treatment challenge, but also necessitates continuous exploration of new therapy targets.
methodsWe used Summary data-based Mendelian Randomization (SMR) analysis, Colocalization (Coloc) analysis, and comprehensive gene expression analysis to probe deep into the genetic causal correlation between the therapeutic target genes of Deer-Antler-Ginseng-Formula (DAGF) and TNBC, and conducted animal experiments to detect the protein expression of the identified drug targets.
resultsFirst and foremost, 1471 drug-target genes of DAGF were retrieved from the TCMSP and BATMAN-TCM databases. Subsequent to the intersection with the differentially expressed genes of breast cancer in TCGA, 221 target genes of DAGF were selected for more comprehensive and systematic analysis. As evidently demonstrated by SMR analysis, 9 genes were genetically causally linked to TNBC. It is particularly noteworthy that 6 genes revealed a negative association with TNBC; 3 genes suggested a positive correlation with TNBC. Nonetheless, nothing more than SPTBN1, PTGFR, and TNNT3 passed the coloc analysis, which demonstrated a significant genetic association with TNBC. Subsequent gene-expression verification and animal experimental models demonstrated TNNT3 is the potential drug target of DAGF for TNBC.
conclusionsThis study demonstrates that DAGF functions as an inhibitor of tumor growth in TNBC xenograft models, with preliminary evidence identifying TNNT3 as a potential therapeutic target. These findings offer novel strategic avenues for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.